BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
Rhea-AI Summary
BridgeBio (Nasdaq: BBIO) will report first quarter 2026 financial results and provide commercial and program updates after market close on Thursday, May 7, 2026.
A conference call and live webcast will begin at 4:30 pm ET. A replay will be available on the company website for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – BBIO
In the Apr 30 session, BBIO gained 0.24%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Earnings date notice | Neutral | +0.8% | Announcement of Q4 and full-year 2025 results call at 4:30 pm ET. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news saw a small positive price reaction around the announcement.
Across recent months, BridgeBio has reported multiple clinical and regulatory milestones while also maintaining a regular cadence of financial communications. A prior earnings date announcement on February 17, 2026 led into fourth quarter and full-year 2025 results, with the stock moving 0.8% over 24 hours. Today’s first quarter 2026 reporting notice continues that pattern of structured updates alongside an advancing pipeline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its first quarter 2026 financial results and business update after the market closes on Thursday, May 7, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
Participants may access the webcast by registering online using the following link, here.
About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
